Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019‐nCoV Infection

Du, Yin; Chen, Xiao-Ping

doi:10.1002/cpt.1844

Cited by 359 publications

(321 citation statements)

References 26 publications

Supporting

Mentioning

292

Contrasting

Unclassified

Order By: Relevance

“…In a recent retrospective cohort study in COVID‐19 patients, Deng et al 34 documented that a 14‐day treatment with lopinavir‐umifenovir (also called arbidol) induced a significant improvement ( P < .05) of clinical symptoms and laboratory finding (virus detection), compared to lopinavir alone. Favipiravir, a purine nucleic acid analog (Table 1) approved for use in influenza, is studied in the management of COVID‐19 35 . In particular, to date (April 14, 2020), 9 clinical trials have been recorded in the World Health Organization database: 7 favipiravir alone (JPRN‐jRCTs041190120, JPRN‐jRCTs031190226, ChiCTR2000030254, ChiCTR2000030113, ChiCTR2000029600, ChiCTR2000029548, ChiCTR2000029544), 1 plus chloroquine phosphate (ChiCTR2000030987), and 1 plus tocilizumab (ChiCTR2000030894).…”

Section: Drug Treatment For Covid‐19mentioning

confidence: 99%

Severe Acute Lung Injury Related to COVID‐19 Infection: A Review and the Possible Role for Escin

Gallelli

Zhang

Wang

et al. 2020

The Journal of Clinical Pharma

View full text Add to dashboard Cite

Acute lung injury (ALI) represents the most severe form of the viral infection sustained by coronavirus disease 2019 (COVID‐19). Today, it is a pandemic infection, and even if several compounds are used as curative or supportive treatment, there is not a definitive treatment. In particular, antiviral treatment used for the treatment of several viral infections (eg, hepatitis C, HIV, Ebola, severe acute respiratory syndrome–coronavirus) are today used with a mild or moderate effect on the lung injury. In fact, ALI seems to be related to the inflammatory burst and release of proinflammatory mediators that induce intra‐alveolar fibrin accumulation that reduces the gas exchange. Therefore, an add‐on therapy with drugs able to reduce inflammation, edema, and cell activation has been proposed as well as a treatment with interferon, corticosteroids or monoclonal antibodies (eg, tocilizumab). In this article reviewing literature data related to the use of escin, an agent having potent anti‐inflammatory and anti‐viral effects in lung injury, we suggest that it could represent a therapeutic opportunity as add‐on therapy in ALI related to COVID‐19 infection.

show abstract

Section: Drug Treatment For Covid‐19mentioning

confidence: 99%

Severe Acute Lung Injury Related to COVID‐19 Infection: A Review and the Possible Role for Escin

Gallelli

Zhang

Wang

et al. 2020

The Journal of Clinical Pharma

View full text Add to dashboard Cite

show abstract

“…The recent reviews published in this journal of the clinical pharmacology of azithromycin 8 and favipiravir 9 as potential COVID‐19 therapies are examples of how Clinical Pharmacology & Therapeutics ( CPT ) aims to contribute to the rapid dissemination of such critical information and knowledge. In addition, rational dosing regimens developed for other infectious diseases may inform best clinical practice for repurposing in COVID‐19 research 10 …”

Section: Figurementioning

confidence: 99%

COVID‐19: A Defining Moment for Clinical Pharmacology?

Graaf

Giacomini

2020

Clin Pharma and Therapeutics

View full text Add to dashboard Cite

“…Currently, there is not any specific effective antiviral treatment for COVID- 19. Although most of the COVID-19 patients have mild or moderate course, up to 5-10% can have severe , potentially life threatening course, there is an urgent need for effective drugs [1].…”

Section: Introductionmentioning

confidence: 99%

Antiviral treatment of COVID-19

2020

View full text Add to dashboard Cite

IntroductionCurrently, there is not any specific effective antiviral treatment for COVID-19. Although most of the COVID-19 patients have mild or moderate course, up to 5-10% can have severe , potentially life threatening course, there is an urgent need for effective drugs [1]. Optimized supportive care remains the mainstay of therapy. As new data regarding clinical characteristics, treatment options, and outcomes for COVID-19 emerges approximately every hour, physicians who are in the care of patients should keep themselves up to date on this issue. There have been more than 300 clinical trials going on, and some of them will be published in the next couple of months. The WHO is launching "Solidarity" clinical trial for COVID-19 treatments to further evaluate remdesivir, hydroxychloroquine/chloroquine, and lopinavir-ritonavir with and without interferon beta 1 . Various other antiviral and immunomodulating agents are 1 World Health Organization (2020). "Solidarity" clinical trial for COVID-19 treatments [online]. Website https://www.who.int/ emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19treatments [accessed 12 April 2020]. 2 Bhimraj A, Morgan RL, Shumaker AH, Lavergne V, Baden5 L et al. Infectious DiseasesSociety of America Guidelines on the Treatment and Management of Patients with COVID-19 Infection [online]. Website https://www.idsociety.org/globalassets/idsa/ practice-guidelines/covid-19/treatment/idsa-covid-19-gl-tx-and-mgmt-4-11-20-1058-am-edt.pdf [accessed 12 April 2020].in various stages of evaluation for COVID-19. A registry of international clinical trials can be found on the WHO website and at ClinicalTrials.gov.At the moment, it is strongly recommended that patients be recruited into ongoing trials, which would provide much-needed evidence on the efficacy and safety of various therapies for COVID-19, given that we could not determine whether the benefits outweigh harms for most treatments [2] 2 .Unless used in the context of randomized clinical trials, antivirals will not be proved to be efficacious or safe for the treatment of COVID-19. In the 2014 Ebola outbreak, close to 30, 000 individuals developed Ebola viral disease, and numerous therapies were tested against this virus, including chloroquine, hydroxychloroquine, favipiravir, brincidofovir, monoclonal antibodies, antisense RNA, and convalescent plasma, among many others. With such a large number of therapeutic interventions given to affected Abstract: Currently, there is not any specific effective antiviral treatment for COVID-19. Although most of the COVID-19 patients have mild or moderate courses, up to 5%-10% can have severe, potentially life threatening course, there is an urgent need for effective drugs. Optimized supportive care remains the mainstay of therapy. There have been more than 300 clinical trials going on, various antiviral and immunomodulating agents are in various stages of evaluation for COVID-19 in those trials and some of them will be publish...

show abstract

Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019‐nCoV Infection

Cited by 359 publications

References 26 publications

Severe Acute Lung Injury Related to COVID‐19 Infection: A Review and the Possible Role for Escin

Severe Acute Lung Injury Related to COVID‐19 Infection: A Review and the Possible Role for Escin

COVID‐19: A Defining Moment for Clinical Pharmacology?

Antiviral treatment of COVID-19

Contact Info

Product

Resources

About